Even as HIV rates fall, Hong Kong can't afford to get complacent
Feel strongly about these letters, or any other aspects of the news? Share your views by emailing us your Letter to the Editor at
letters@scmp.com or filling in
this Google form . Submissions should not exceed 400 words, and must include your full name and address, plus a phone number for verification
Hong Kong has made remarkable progress in HIV prevention. In 2024, the city recorded just
365 new HIV cases – the ninth consecutive year of decline since peaking in 2015. The prevalence rate among the general population stands at 0.1 per cent, far below the 2023 global average of 0.6 per cent.
This is undoubtedly encouraging and worthy of recognition, but progress does not equal victory. Complacency would be a costly mistake, especially with Hong Kong still some distance away from achieving the goal of ending HIV as a public health threat by 2030.
Beneath the encouraging figures lie troubling trends. Many new cases are late presenters – people whose CD4 cells have dropped to a very low level or those with an Aids-defining illness when they seek care.
A significant number of late presenters do not belong to high-risk populations. Prevention and outreach strategies may have blind spots. Stigma also remains a barrier. The fear of being judged continues to deter people from getting tested and receiving timely treatment, threatening to unravel hard-won gains.
To strengthen progress, Hong Kong must forge deeper cross-sectoral collaboration. Continued investment in prevention is essential; it must expand. While government support has been crucial, the private sector must step up, too. This approach mirrors mainland China's 2024 State Council directive, which called for the mobilisation of society-wide support for HIV prevention.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
3 hours ago
- South China Morning Post
Chinese swimmers had to have eaten 5kg of food to fail 2021 drug tests, Usada chief says
The head of the United States Anti-Doping Agency told senators that Chinese swimmers would have had to eat around 11 pounds (5kg) of food to test for the amounts of the performance enhancer that resulted in the much-debated positive drug tests from 2021 that were later disregarded. Advertisement 'It's unbelievable to think that Tinkerbell just showed up and sprinkled it all over the kitchen,' Travis Tygart said in a Senate hearing on Tuesday focused on the World Anti-Doping Agency's response to the doping case. A key part of that case was Wada's acceptance of the explanation from Chinese authorities that the swimmers had been contaminated by traces of the drug trimetazidine (TMZ) in a hotel kitchen. Usada scientists analysed data from a report commissioned by Wada to come up with the amount of food (5kg) or liquid (4.9 litres) the athletes would have had to have consumed to test positive at the levels they did. Wada officials declined to participate in the hearing, which spokesperson James Fitzgerald called 'another political effort led by Travis Tygart … to leverage the Senate and the media in a desperate effort to relitigate the Chinese swimming cases and misinform athletes and other stakeholders'. Advertisement Also testifying was former US drug tsar Rahul Gupta, whose decision at the start of this year to withhold US$3.6 million in funding – the biggest single chunk that Wada receives on an annual basis – furthered a long-running feud between US and Wada authorities.
South China Morning Post
7 hours ago
- South China Morning Post
Hong Kong to launch database for high-risk elderly carers this year
Hong Kong will launch a database this year to identify high-risk carers looking after the elderly, with the city recording more than 470 suicides among older residents annually, accounting for over 40 per cent of all cases. Secretary for Labour and Welfare Chris Sun Yuk-han said on Wednesday that the government was in discussions with the personal data privacy authorities to design data-sharing solutions that complied with the city's legal requirements. But he added that the government hoped to launch the new database as soon as possible this year. '[Authorities] and the Privacy Commissioner have roughly resolved how to connect and compare databases in accordance with the Personal Data (Privacy) Ordinance, but we will launch a pilot scheme first,' Sun told lawmakers at a Legislative Council meeting. 'We hope to launch the pilot scheme as soon as possible this year.' Statistics from the Coroner's Court showed that there were 472 suicides involving people aged 60 and above last year, on a par with the 473 and 477 recorded in 2023 and 2022, respectively. The database will include information on carers looking after older residents and those from low-income households. Photo: Eugene Lee The suicides of those aged 60 and over accounted for 41 per cent of the city's overall cases last year, slightly down from 43 per cent in 2023 and 44 per cent in 2022.
South China Morning Post
14 hours ago
- South China Morning Post
MingMed seeks Hong Kong listing to fund research and launch Botox alternative
MingMed Biotechnology is seeking a Hong Kong listing this year to raise funds to research and market a genetically engineered alternative to Botox in China. The drug developer, based in the Nansha district of Guangzhou, said it would set up an incubation centre in the Hong Kong Science and Technology Park in the third quarter. 'Hong Kong has many good universities and research institutes, but it [does not have] a lot of innovative biotech firms,' said MingMed CEO Zhang Yan in an interview on Friday. 'We aim to [turn] early-stage research discoveries at the city's universities into commercial products.' He said Hong Kong was a good platform for fundraising , early-stage drug research and global commercialisation, while Nansha was an ideal location for research and manufacturing. MingMed has raised 1.75 billion yuan (US$243.7 million) from multiple private fundraisings, Zhang said, adding that its largest institutional investor was Beijing-based Gaorong Ventures. The company filed a Hong Kong listing application in 2022, but let it lapse due to unfavourable global market conditions for biotech stocks, he said. Last year, MingMed completed a late-stage, phase-three clinical trial on a genetically manipulated alternative to Botox, which is used to reduce wrinkles. Botox is made from a naturally occurring botulinum toxin, a protein produced by a bacterium. Genetically engineered products could lower production costs and enhance product safety, Zhang said.
